

Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature

Peck, M.W.¹, Smith, T.J.², Anniballi F.³, Arnon, S.S.⁴, Austin, J.W.⁵, Bano, L.⁶, Bradshaw, M.⁷, Cuervo, M.P.⁸, Cheng, L.W.⁹, Derman, Y.¹⁰, Dorner, B.G.¹¹, Dover, N.⁴, Fisher, A.¹², Hill, K.K.¹³, Kalb, S.R.¹⁴, Korkeala, H.¹⁰, Lindström, M.¹⁰, Lista, F.¹⁵, Lúquez, C.¹⁶, Mazuet, C.¹⁷, Pellett, S.⁷, Pirazzini, M.¹⁸, Popoff, M.R.¹⁷, Rossetto, O.¹⁸, Rummel, A.¹⁹, Sesardic, D.²⁰, Singh. B.R.²¹, and Stringer, S.C.¹

¹*Institute of Food Research, NR4 7UA, Norwich, England, UK*

²*Molecular and Translational Sciences Division, United States Army Medical Institute of Infectious Diseases, Fort Detrick, Maryland, USA*

³*National Reference Centre for Botulism, Istituto Superiore di Sanita, Rome, Italy*

⁴*Infant Botulism Treatment and Prevention Program, California Department of Public Health, Richmond, California, USA*

⁵*Bureau of Microbial Hazards, Health Canada, Ottawa, Ontario, Canada*

⁶*Istituto Zooprofilattico Sperimentale delle Venezie, Treviso, Italy*

⁷*Department of Bacteriology, University of Wisconsin, Madison, Wisconsin, USA*

⁸*Área de Microbiología, Departamento de Patología, Universidad Nacional de Cuyo, Mendoza, Argentina*

⁹*Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, U.S. Department of Agriculture, Albany, California, USA*

¹⁰*Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland*

¹¹*Robert Koch Institute, Berlin, Germany*

¹²*Applied Physics Laboratory, Johns Hopkins University, Baltimore, Maryland, USA*

¹³*Los Alamos National Laboratories, Los Alamos, New Mexico, USA*

¹⁴*National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA*

¹⁵*Army Medical and Veterinary Research Center, Rome, Italy*

¹⁶*National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA*

¹⁷*Institut Pasteur, Bactéries anaérobies et Toxines, Paris, France*

¹⁸*Biomedical Sciences Department, University of Padova, Padova, Italy*

¹⁹*Institut für Toxikologie, Medizinische Hochschule Hannover, Hannover, Germany*

²⁰*National Institute for Biological Standards and Control, a centre of Medicines and Healthcare Products Regulatory Agency, Hertfordshire UK.*

²¹*Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, Massachusetts, USA*

Corresponding author: M. W. Peck (Mike.peck@ifr.ac.uk).

Abstract

Botulinum neurotoxins are diverse proteins. They are currently represented by at least seven serotypes and more than 40 subtypes. New clostridial strains that produce novel neurotoxin variants are being identified with increasing frequency, which presents challenges when organizing the nomenclature surrounding these neurotoxins. Worldwide, researchers are faced with the possibility that toxins having identical sequences may be given different designations, or novel toxins having unique sequences may be given the same designations on publication. In order to minimize these problems, an *ad hoc* committee consisting of over 20 researchers in the field of botulinum neurotoxin research was convened to discuss clarification of the issues involved in botulinum neurotoxin nomenclature. This publication presents a historical overview of the issues and provides guidelines for botulinum neurotoxin subtype nomenclature in the future.

1) Historical perspective of botulinum neurotoxin serotypes

Botulinum neurotoxins (BoNTs) are the most potent naturally-occurring substances, with as little as 50 ng of neurotoxin sufficient to cause human botulism. This minimal lethal dose is estimated from data on the amount of neurotoxin consumed in cases of foodborne botulism and from animal experiments [1-3]. Botulinum neurotoxins are 150 kDa proteins that are comprised of a heavy chain (HC-100 kDa) and a light chain (LC-50 kDa). The heavy chains have two functional domains, with the C-terminal domain (H_C) involved in neurotoxin binding to specific receptors in peripheral nerve terminals (Table 1), and the N-terminal domain (H_N) involved in translocation of the light chain into the nerve cell cytoplasm [4-6]. The light chains are zinc metalloproteases that block release of the neurotransmitter, acetylcholine, in cholinergic nerves by specific cleavage of SNARE (soluble (N-ethylmaleimide-sensitive factor (NSF) attachment receptor proteins) (Table 2)) leading to flaccid paralysis and botulism [7-9].

Serological methods were first used to distinguish botulinum neurotoxins more than a century ago. Leuchs [10] showed that botulinum neurotoxins formed by strains of *Clostridium botulinum* isolated following outbreaks of foodborne botulism in Ellezelles (Belgium) and Darmstadt (Germany) were antigenically distinct, with antitoxin raised against one neurotoxin not cross-neutralizing neurotoxin formed by the other strain. Using a similar approach, Burke [11] also recognized two antigenically distinct botulinum neurotoxins, and designated these as serotypes A and B. Strains that formed type A neurotoxin were reported to dominate in the western USA, and strains that formed type B neurotoxin dominated in the eastern USA [12,13]. These pioneering studies established the use of serological methods based on type-specific antitoxins to define and distinguish botulinum neurotoxin serotypes using small animal models. In the decades since Leuchs' and Burke's work, application of the neurotoxin neutralization assay using serotype-specific antisera led to the recognition of seven confirmed botulinum neurotoxin serotypes (types A to G). A potential eighth type ("type H") was described in 2013, Recent reports have variously described this novel neurotoxin as BoNT/H, BoNT/FA or BoNT/HA [14-20].

Historically, the use of serological methods to identify and characterize botulinum neurotoxins has not been without problems. In 1924 (only a few years after the work of Leuchs and Burke), problems were encountered when serotyping neurotoxin formed by newly identified BoNT/C strains that were tested using specific antisera. It was found that antisera produced from type C strains that were isolated from fly larvae and chickens were able to neutralize type C neurotoxin from several strains isolated in the USA, as well as the “Seddon” type C strain that was isolated from cattle with botulism in Australia, but that antisera produced from the “Seddon” strain neutralized only its homologous toxin [21]. It is now known that these “type C” toxins are BoNT/CD chimeras composed of 2/3 type C and 1/3 type D sequence, whereas true type C1 toxins are produced by Seddon-like strains [22].

Similar issues arose in the serotyping of toxins from multiple type A and type F strains in Argentina [23,24]. Significant differences in the efficiency of neutralization were noted, particularly among the BoNT/F toxins. These observations led the researchers to conclude, *“there is a general tendency to accept the antigenic homogeneity of the botulinum toxins within each type, and from the year 1924 in which the serological relations among the type C strains were described, later denominated type Ca and Cβ (currently C/D and C1), up to this date it was never known with precision what to do with these strains, from the point of view of their classification. But the biologic reality is that there are serologic variations of differing magnitude in strains within each type, evidenced by significant differences in antitoxin consumption in cross neutralization, being the most obvious cases those observed in the strains of type C and F”* [23].

These observations pointed to a level of intratypic serological diversity that underlies the “serotype” designations. It was recognized that these differences may have an impact on the effectiveness of botulism treatment, as antitoxins have been raised against a single toxin subtype per serotype. For example, all currently produced commercial botulinum antitoxins were produced following vaccination with BoNT/A1, /B1, or either /E1 or /E3 toxoids. The few research studies that have been published evaluating the effectiveness of such antisera have shown differential protection against the spectrum of toxins within a single serotype [25,26]. In order to provide adequate protection, current antitoxin treatments require administration of high

volumes of proteinaceous material [27,28], which increases the risk of adverse reactions. In addition, the impact of intratypic serological diversity on the effectiveness of current antitoxin treatments remains largely unknown.

2) Historical perspective of botulinum neurotoxin subtypes

Early work had suggested that each strain of *C. botulinum* formed a single type of botulinum neurotoxin. However, using mouse tests and specific antisera, Giménez and Ciccarelli described a strain that formed two distinct types of neurotoxin, with a major amount of type A toxin activity and a minor amount of type F toxin activity [29]. This strain was designated type A, subtype Af [23]. A number of strains are now described that form more than one type of botulinum neurotoxin [30-32]. For more than a decade now, however, the term subtype has been used in a different way, which is to describe intratypic neurotoxin variation based on the amino acid sequence of the neurotoxin (that has been derived following sequencing of the neurotoxin gene). A numerical notation has also been introduced, so that the subtypes are designated BoNT/A1, BoNT/A2, BoNT/A3, etc. [32-38] (Table 3).

The development of techniques to enable the sequencing of individual genes has substantially increased our understanding of botulinum neurotoxin diversity. Within a three year time span (1990-1993), sequences representing one member from each of the seven neurotoxin serotypes became available [39-47]; five years after initial sequences for each serotype were made public, sequences for eight alternative neurotoxin subtypes had been published [22,47-52]. Five of these subtypes were known to differ in some way from the “reference” toxins for each serotype prior to sequencing. For example, a strain that produces a type A1 toxin and contains a nonfunctional BoNT/B gene (an A1(B) strain) was only differentiated using PCR assays that detected the presence of the unexpressed “silent” B gene in the absence of BoNT/B [53].

The first *C. botulinum* whole genome sequence was published in 2007 [36], and many full genomes in addition to individual neurotoxin-encoding genes have been sequenced. Sequencing has confirmed the distinctiveness of the seven botulinum neurotoxin serotypes (types A to G), with amino acid differences between the seven neurotoxin serotypes ranging from 37.2% to 69.6% [54] (Table 4). Furthermore, studies of the functionality of the botulinum neurotoxins also

support the classification of seven serotypes. Botulinum neurotoxin light chains possess endopeptidase activity, and selectively cleave proteins of the neurotransmitter vesicle docking/fusion complex, preventing formation of a stable complex [8,9]. BoNT/A, C and E cleave SNAP-25 at distinct sites; BoNT/B, D, F and G cleave VAMP-1/2/3 at distinct sites; BoNT/C can also cleave Syntaxin 1A/C (Table 2). Each neurotoxin subtype within a serotype cleaves its target substrate at the same single conserved peptide bond, except for BoNT/F5 (Table 2) [55].

The technology resulting in the production of monoclonal antibodies provided a new way of evaluating these toxins serologically. Monoclonal antibodies developed against BoNT/A [56], BoNT/B [57], BoNT/C1 [58], and BoNT/E [59] were used to develop new toxin detection assays, and also to discover new aspects of toxin structure and activity. However, these antibodies have been of limited use as predictors of subtype-level differences, since monoclonal antibody epitopes are, at most, limited to 5-7 continuous or discontinuous amino acids. Many toxin subtypes are very closely related, so that most monoclonal antibodies will bind multiple toxin subtypes, severely limiting their discriminating power and making them unsuitable for toxin subtype determinations.

Initial studies using monoclonal antibodies, however, often reported that the antibodies would neutralize some, but not all, subtypes of a specific serotype, suggesting variability within each neurotoxin serotype [33,60,61]. The extent of this variability is now being revealed through sequencing of whole genomes and individual neurotoxin-encoding genes. A landmark article on sequence variation among botulinum neurotoxin serotypes published in 2005 described within-serotype variations among neurotoxin sequences as being of two types: those that were virtually identical and those that were more variable and differed by at least 2.6% in amino acid sequence. This observation was based on a study of 49 neurotoxin sequences (each serotype, with the exception of type G, was represented by 4-17 sequences) [34]. Subsequent studies sorted these and additional toxin gene sequences into differing phylogenetic clades, which were then identified as new subtypes [62,63]. The identification of novel subtypes thereby been based primarily on the sequence of the botulinum neurotoxin gene and/or derived amino acid sequence.

There are more than forty neurotoxin subtypes presently described in the literature (Table 3; Figure 1).

It has been suggested that a *C. botulinum* neurotoxin could be defined as a distinct subtype if it encoded a protein sequence that differed from the prototype neurotoxin by at least 2.6% [35,62,64-72]. A recent was conducted comparing neurotoxin sequences from 127 BoNT/A, 91 BoNT/B, 23 BoNT/C and BoNT/D, 235 BoNT/E, and 50 BoNT/F producing strains obtained from various sources; the results are reported in Tables 4-9. The sequences include published and unpublished sequences, many of which were identical. While no particular efforts to publicly post the redundant sequences were made, examples of each subtype, including strain name, source and GenBank accession number, are listed in Table 4. Figures 2-6 illustrate the range of sequence diversity among these strains. While most presently described subtypes differ from each other by more than 2.6% at the amino acid level, some BoNT/B subtypes and BoNT/E subtypes do not meet this criterion (Tables 6 and 8). Additionally, it is more common for strains of *C. botulinum* Group III to form a chimeric or hybrid protein that combines elements of BoNT/C and BoNT/D neurotoxin, rather than a distinct BoNT/C or BoNT/D neurotoxin (Table 7; Figure 4).

Discussions as to the relationship between sequence differences and potential immunological or functional differences have led to studies comparing toxin characteristics versus sequence. The majority of these studies involved differential binding to antibodies. As expected, binding differences were more noticeable when monoclonal antibodies were used, but quantitative differences were also noted with assays involving polyclonal antibodies [25,34]. However, as noted above, these immunological differences cannot reliably identify distinctive toxin subtypes.

Biological and functional activities are presumed to be largely conserved within individual neurotoxin serotypes. Currently, the only naturally-occurring amino acid sequence changes that have led to functional differences were reported with subtype BoNT/F5, whose enzymatic domain differs from all other BoNT/F enzymatic domains by greater than 50% in amino acid sequence (Table 2), leading to differences in the enzymatic target site [55]. All other subtypes within a serotype utilize the same enzymatic cleavage target substrates and sites.

Even though studies of toxin:receptor interactions of subtypes is limited, current information indicates that all toxin subtypes within a serotype also interact with the same receptor targets (Table 1), with one exception. BoNT/DC interacts with synaptotagmin 1 & 2; the putative receptor for BoNT/D is N-glycosylated SV2A and B; and BoNT/C appears to interact solely with gangliosides [73-75]. This difference may not be too surprising, as BoNT/DC is a hybrid toxin with a BoNT/C-like receptor-binding domain that differs in amino acid sequence from BoNT/D by 60.2% and from BoNT/C by 22.2%. These differences have directed different receptor interactions for each of the toxins. It should also be noted that subtype quantitative binding differences to receptors were seen with two BoNT/B subtypes. BoNT/B1 and BoNT/B2 both interact with synaptotagmin, but BoNT/B1 binds both synaptotagmin 1 and 2, with binding affinities of 3.4 and 0.52 nM, respectively, while BoNT/B2 binds only synaptotagmin 2, with an intermediate binding affinity of 2.4 nM [33]. There is a significant amino acid sequence difference (8.1%) in the receptor binding domains of BoNT/B1 and BoNT/B2. BoNT/A8 has also been reported to have a reduced affinity to ganglioside receptors compared to BoNT/A1 [71]. Additional differences in catalytic activity have also been described among BoNT/A subtypes [76-80].

It is presently not feasible to use biological, structural, immunological or functional characteristics to subtype botulinum neurotoxins, as knowledge is limited. However, a sequencing-based approach can be used to rapidly categorize botulinum neurotoxin subtypes, to avoid confusion in the literature and to facilitate future research endeavors. One important benefit of this approach is that it allows for comparison of neurotoxins formed by strains located in different laboratories.

When analyzing presently published toxin subtypes, in which subtype categorization has been based on amino acid sequence differences, it is important to recognize that each serotype shows a unique pattern of between-subtype and within-subtype differences (Tables 5-9). In the case of BoNT/A, inter-subtype differences range from 2.9-15.6% (Table 5; Figure 2). Intra-subtype differences are much smaller ($\leq 0.8\%$, with one exception), thereby providing a sufficient margin of discrimination in sequences that are within subtypes versus those between subtypes. The

exception is strain CDC 2171, which differs from other BoNT/A2 by $\sim 2.5\%$. Due to an apparent recombination event, this toxin shares 100% identity with BoNT/A2 Kyoto-F for approximately 2/3 of the sequence, but differs by 5.6% in the terminal Hc region of the molecule. The margin of discrimination among BoNT/A subtypes is similar to the scenario with most BoNT/F subtypes, where inter-subtype differences range from 3.0-36.2%. Intra-subtype differences are $\leq 0.6\%$ with the exception of BoNT/F7, which shows an intra-subtype difference of 1.7% among the eight sequences that were analyzed (Table 9). Removal of a single BoNT/F7 sequence, from strain ATCC 43756, results in a reduction in variability within this subtype from 1.7 to 0.8%.

BoNT/E subtype sequences, with the exception of BoNT/E9 and BoNT/E12, are closely related (Figure 5). Amino acid differences among BoNT/E1-BoNT/E8 range from 0.9-5.9%, but intra-subtype differences of 0.1-0.2% are seen within BoNT/E1, BoNT/E2, BoNT/E4-6 and BoNT/E11 subtypes (Table 8). The lone BoNT/E9 strain sequence differs from BoNT/E1-8, BoNT/E10, and BoNT/E11 by 10.1-11.8% in amino acid residues, making it distinctive among the BoNT/E subtypes [68]. One issue that has arisen when distinguishing different subtypes having limited differences has been the use of phylogenetic clade analysis of neurotoxin nucleotide sequences, instead of comparisons of their amino acid differences, as the basis for discrimination [62,81]. While BoNT/E1, BoNT/E2, and BoNT/E3 clearly sort into distinct, but closely related, phylogenetic clades [81,82], amino acid analysis of their sequences shows their differences range from 0.9 to 1.8% when BoNT/E2 and BoNT/E3 are compared to BoNT/E1 (Table 8). If the 2.6% amino acid difference guideline had been applied, this would be considered a single larger subtype. While it has been decided that historical subtype designations will continue to be used (see below), it is useful to understand that BoNT/E1, BoNT/E2, and BoNT/E3 could be considered as a single subtype entity. The effect of analyzing large numbers of sequences is seen with BoNT/E3 (toxin sequences from 143 strains) and BoNT/E10 (toxins sequences from 36 strains), where intra-subtype sequence differences were 0.6% and 0.8%, respectively. It is possible that as additional toxin sequences become available, intra-subtype differences may increase.

BoNT/B shows the greatest degree of intra-subtype variability of any serotype. (Figure 3). Inter-subtype differences range from 1.6%-7.1% and intra-subtype differences range from 0.8-2.1%. A clear relationship can be seen among BoNT/B2, BoNT/B3, and BoNT/B6 (within-subtype amino acid differences of 1.6-1.9%), which is similar to the situation with BoNT/E1, BoNT/E2, and BoNT/E3. BoNT/B2, BoNT/B3, and BoNT/B6 were also initially differentiated using phylogenetic clade analysis, not amino acid differences [62,63], with the result that BoNT/B2, BoNT/B3, and BoNT/B6, like the BoNT/E1/E2/E3 grouping, could be considered a single subtype. In addition, with BoNT/B the within-subtype variability is higher overall than with other toxin types, ranging from 0.8-1.9%. The BoNT/B2 and BoNT/B4 subtypes are particularly variable. With the BoNT/B2, BoNT/B3, and BoNT/B6 toxins, a wide range of amino acid differences is seen (Table 6). This unique ranging of BoNT/B2 and related subtypes may indicate that horizontal genetic interactions between certain BoNT/B-producing strains show a higher level of activity than that seen among other serotypes.

These recombination events may be the major factor responsible for the proliferation of subtypes seen within this toxin. It is important to note these events as part of toxin characterizations; however, attempts to define the toxin subtypes on the basis of these events could become challenging. A prime example is the current dispute over the nomenclature for the newly described novel toxin known as BoNT/H, BoNT/HA or BoNT/FA, depending on how it is characterized [14-20].

3) Historical perspective of botulinum neurotoxin forming clostridia

Historically, the production of a botulinum neurotoxin was the only criterion for the species nomenclature for these strains, so that all botulinum neurotoxin-producing clostridia were known as *Clostridium botulinum*. Today, at least six physiologically and genetically distinct bacteria are known to form botulinum neurotoxins [36,53,62,83-87]. Currently recognized species include *C. botulinum* Groups I – IV, some strains of *C. baratii*, *C. butyricum* [88], and possibly also neurotoxin-producing *C. sporogenes*. *C. botulinum* comprises four discrete groups of bacteria. *C. botulinum* Group I (proteolytic *C. botulinum*) strains are mesophilic and form spores of high heat resistance [84]. *C. botulinum* Group I strains produce BoNT/A, BoNT/B, many of which were identical and/or BoNT/F. The number of neurotoxin genes located in the Group I

genomes and the number of neurotoxins produced is variable, with strains possessing up to three neurotoxin genes, and producing one, or more rarely, two or three distinct neurotoxins [85]. Nontoxic representatives have also been isolated. *C. botulinum* Group I strains are primarily responsible for human botulism. *C. botulinum* Group II (non-proteolytic *C. botulinum*) strains are psychrotrophic and form spores of moderate heat resistance [84]. *C. botulinum* Group II strains produce either BoNT/B, BoNT/E or BoNT/F. Group II strains are not known to produce multiple toxins, however sequencing of the genomes of *C. botulinum* Group II BoNT/F6 strains revealed that they also contain fragments of a type B and a type E neurotoxin gene [91]. Nontoxic strains have been described [92]. *C. botulinum* Group II causes human botulism. Neurotoxin encoding genes of *C. botulinum* Groups I and II are located on the chromosome or on a plasmid [31,38,54,65,84,85,93-96]. *C. botulinum* Group III strains, also included in *C. novyi sensu lato* [86], are mesophiles and cause botulism in various animal species. Strains form BoNT/C or BoNT/D, although more frequently a hybrid CD or DC neurotoxin is identified [22,97]. *C. botulinum* Group IV (also known as *C. argentinense*) strains form BoNT/G, which has not been definitively associated with human or animal botulism [98]. Some strains of *C. baratii* form type F neurotoxin, and some strains of *C. butyricum* form type E neurotoxin; both are associated with human botulism [88]. It has also recently been noted that some BoNT/B-producing strains formerly thought to be within *C. botulinum* Group I may be neurotoxic strains of *C. sporogenes* [38,64,89,90].

The earliest botulinum neurotoxin variants described were that of a type B neurotoxin formed by a strain of *C. botulinum* Group II and a type A neurotoxin formed by a *C. botulinum* Group I strain [99,100]. However, these differences were not due to characteristics of the neurotoxin, but rather to characteristics imparted by the bacteria themselves. The neurotoxin is formed as a progenitor toxin, a single 150 kDa polypeptide. Strains of *C. botulinum* Group I produce proteolytic enzymes that are responsible for post-expression processing of the neurotoxin, leading to a more active di-chain structure with a 50 kDa light chain attached to a 100 kDa heavy chain by a disulfide bond [101]. Strains of *C. botulinum* Group II lack these enzymes, and the neurotoxin remains as a single polypeptide chain to be fully activated by host proteases [102].

4. Developing a way forward with regard to a nomenclature for botulinum neurotoxin subtype

While the identification of neurotoxin serotypes and subtypes has aided in understanding the epidemiology of neurotoxin-producing clostridia and in the development and screening of effective diagnostics and treatments for botulism, the increasing numbers of toxin subtypes that are being identified has posed a challenge for researchers. New toxin variants are constantly being discovered, and there is confusion as to the range of variation within each subtype. It is not always apparent whether a “new toxin” should be described as a new “subtype” or not, and what is the correct designation for this neurotoxin. For example, multiple laboratories may be publishing the same neurotoxin subtypes as different designations without the knowledge that they are related, or identical neurotoxin subtypes may be identified as a particular neurotoxin subtype in one publication and as another neurotoxin subtype in a different publication. The nomenclature picture is confusing and a systematic approach to neurotoxin subtype nomenclature is urgently needed.

To address this issue, a committee was formed to consider the problem and propose solutions. Initial efforts involved a survey of researchers working on various aspects of botulinum neurotoxin research. Seventy-eight responses were received.

- The majority felt that nomenclature standardization was somewhat or very important
- The majority preferred the term “toxin subtype” to best describe within serotype toxin differences
- The highest importance was given to single nucleotide or single amino acid differences (which is problematical as this would lead to hundreds and potentially thousands of subtypes and cease to be meaningful); however half of the responders felt the nomenclature should be also be based on functional differences.

A group of more than twenty researchers from North and South America and Europe then volunteered to participate in the drafting of guidelines designed to aid researchers with neurotoxin subtype nomenclature. In addition, the feasibility that a database could be set up to analyze submitted toxin sequences and determine for the researcher if their neurotoxin is a new

or existing subtype was investigated. A second questionnaire was sent to each volunteer to further clarify the consensus opinions for nomenclature guidelines. There was agreement on several issues:

- 1) The best term to describe within serotype differences was “subtype”.
- 2) Subtype discrimination should be based on protein sequences derived from sequencing of the encoding gene, which can be obtained quickly and shared among the botulinum research community as a whole
- 3) Previously published subtypes should be maintained as identified, with adjustments being made only to avoid confusion
- 4) There was a need for a specialized screening system to aid in organizing subtype nomenclature, and new sequences should be submitted to public databases as soon as practically possible.

5. The proposed way forward with regard to a nomenclature for botulinum neurotoxin subtype

The unique characteristics of the different subtypes within each serotype and their relationships with each other make selection of a single standard problematic. However, the objective here is to provide a level of organization in nomenclature, not to provide detailed, exacting categorization of each new toxin that is discovered. The majority of the approximately forty botulinum neurotoxin subtypes presently described in the literature were based on the amino acid sequence of the proteins, derived from the encoding gene. A study of 49 neurotoxin sequences, published in 2005, reported that subtypes differed by at least 2.6% in amino acid sequence [34]. Although this is a relatively arbitrary cut-off, it has provided the basis for most genetic subtype designations for the past decade. More than 500 neurotoxin sequences were recently compared, and 41 distinct subtypes have been identified (Tables 5-9). Although most of the described subtypes differed by more than 2.6% at the amino acid level, some BoNT/B and BoNT/E subtypes did not [103].

This raises the question as to whether (i) the present subtypes should be accepted, or (ii) a cut-off of 2.6% difference should be rigidly applied and some neurotoxin subtypes re-designated. There is also the issue of how subtypes should be identified in the future. The committee proposes that:

- 1) Subtypes should be determined from the amino acid sequence derived by gene sequencing.
- 2) Current subtypes named in the literature will be retained (except where either two distinct neurotoxins are given the same subtype, or one neurotoxin is known as two subtypes) (Table 3). This would include retention of subtypes BoNT/B2, BoNT/B3, and BoNT/B6, which differ by 1.6-1.9%; BoNT/E1 with BoNT/E2 or BoNT/E3, which differ by 1.0-1.8%; and BoNT/E1 with BoNT/E7 or BoNT/E8, which differ by 1.8-2.2%.
- 3) All future designated subtypes must differ from any known subtypes by more than 2.6% at the amino acid level, and to avoid future confusion a centralized procedure will be used to aid in determining whether newly discovered toxins are unique subtypes and assigning appropriate subtype designations to these toxins.
- 4) As this nomenclature is based on the protein sequence derived following sequencing of the encoding gene, it is proposed that the term “subtype” or “genetic subtype” be used to distinguish from nomenclature based on serotyping alone (as in “subserotype”).
- 5) All publications on BoNTs should disclose not only the serotype and subtype designations of the toxin, but also the strain it is derived from, and the source of the strain. The toxin sequences should also be publically posted (e.g. GenBank), and the accession number given.

It is recognized that this scheme considers all amino acid changes as equivalent and that some changes will be more significant than others. Furthermore this scheme should not be construed to predict biological function, structure, or reflect neurotoxin evolution, but is rather a way of broadly categorizing related neurotoxin sequences and perhaps allowing investigators to target specific sequences for further study.

Additionally, it is apparent that some of the present neurotoxin subtypes are a hybrid of other subtypes. For example, BoNT/A2 is a hybrid of BoNT/A1 and BoNT/A3 [62], and BoNT/F6 is a hybrid of BoNT/F1 and BoNT/F2 [85]. The designation of these hybrids as distinct subtypes is supported, but it should be noted in manuscripts that these are hybrids. It is recognized that a majority of BoNT/C and BoNT/D are hybrids, which are not given numeric appellations, but are

reported as BoNT/CD or BoNT/DC chimeric toxins [22]. Two exotoxins expressed simultaneously with BoNT/C and/or BoNT/D, which are not neurotoxins, have been designated as type C2 and C3 toxins [104]. In order to avoid confusion with the hybrid botulinum neurotoxins and the C2 and C3 toxins, the terms BoNT/CD and BoNT/DC will continue to be used to designate hybrid BoNT/C and /D subtypes.

6. Development of a screening system for preliminary identification of novel botulinum neurotoxin subtypes

The system for clarification of toxin subtype would function as follows:

- 1) Prior to publication, a researcher would determine the neurotoxin amino acid sequence following sequencing of the encoding gene, and compare it to known subtype sequences.
- 2) A table relating percent differences with selected and representative sequences of known subtypes (a “profile”: see Table 3) but not the actual sequence would be submitted to the Centers for Disease Control and Prevention, Atlanta, Georgia, USA (bontsubtype@cdc.gov). If desired, the actual sequence may be submitted instead.
- 3) The profile would be compared with all profiles currently in the CDC database. If there is a match, this would most likely indicate that the toxin was a member of a known (published or yet unpublished) subtype. If there was no match, the profile would be considered to be unique, indicating that it was a novel subtype.
- 4) This information, along with the subtype designator reserved for a defined period of time, would be relayed to the researcher for publication.

The actual toxin sequence would remain with the researcher throughout the procedure until it is published. This ensures control of the data while clarifying its classification. It is stressed, however, that the toxin sequences should be publically posted (e.g. GenBank) and published as soon as possible, and that publications should clearly state the strain and its source, its subtype, and the deposited sequence accession number.

7. Summary

For several decades, the standard method for identifying and characterizing botulinum neurotoxins has involved animal tests using serotype-specific antisera, with the range of variation in response to these toxins occasionally providing challenges as to the assignment of specific serotypes. In addition, the reagents necessary for these procedures are becoming scarce, and there is a strong desire to minimize the use of experimental animals. The ability to sequence neurotoxin genes and derive the associated neurotoxin protein sequence has become widespread over the past 25 years, and has revealed not only details concerning serotype and subtypes, but also underlying variation that might not be noticed when using serotyping antisera. The proliferation of inexpensive, rapid sequencing methods has enabled laboratories worldwide to characterize neurotoxins in this consistent way. We note for future consideration that there is a developing interest in the potential of classifying botulinum neurotoxins based on their enzymatic activity (including substrate cleavage patterns).

We propose to take advantage of sequencing methods to categorize botulinum neurotoxin subtypes, and to clarify subtype nomenclature through a screening system of new neurotoxin sequences that will eliminate uncertainties as to the nomenclature of these toxins. A database will be used to compare neurotoxin sequence differences with known toxin subtypes and provide guidelines as to whether the newly submitted sequences are related to known toxin subtypes, or whether they represent novel subtypes that can be published as such with confidence.

Acknowledgements

MWP and SCS are grateful for support from the BBSRC Institute Strategic Programme on Gut Health and Food Safety [grant number BB/J004529/1]. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U. S. Department of Defense. We gratefully acknowledge Mr. William Discher, USAMRIID (in generating the figures for this publication) and Christine Rasetti-Escargueil.

References

1. S.S. Arnon, R. Schechter, T.V. Inglesby, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, J. Hauer, M. Layton, S. Lillibridge, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, D.L. Swerdlow, K. Tonat, B. Working Group on Civilian, Botulinum toxin as a biological weapon: medical and public health management, *JAMA*, **285**(8), 1059-1070 (2001)
2. C.E. Dolman, L. Murikami, Clostridium botulinum type F with recent observations on other types, *J Infect Dis*, **109**(2), 107-128 (1961)
3. T.J. Smith, V.I. Roxas-Duncan, L.A. Smith, Botulinum neurotoxins as biothreat agents, *J Bioterr Biodef*, **S7**(003), (2012)
4. A. Rummel, The long journey of botulinum neurotoxins into the synapse, *Toxicon*, (2015) (in Eng)
5. O. Rossetto, M. Pirazzini, C. Montecucco, Botulinum neurotoxins: genetic, structural and mechanistic insights, *Nat Rev Microbiol*, **12**(8), 535-549 (2014)
6. A. Fischer, M. Montal, Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function, *Toxicon*, **75**, 101-107 (2013)
7. B. Poulain, M. Popoff, J. Molgo, How do the botulinum toxins block neurotransmitter release: from botulism to the molecular mechanism of action, *Botulinum J*, **1**(1), 14-87 (2008)
8. S. Pantano, C. Montecucco, The blockade of the neurotransmitter release apparatus by botulinum neurotoxins, *Cell Mol Life Sci*, **71**(5), 793-811 (2014)
9. T. Binz, Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission, *Curr Top Microbiol Immunol*, **364**, 139-157 (2013)
10. J. Leuchs, Beitrage zur kenntnis des toxins und antitoxins des Bacillus botulinus., *Z Hyg Infektionskr*, **76**, 55-84 (1910)
11. G.S. Burke, Notes on *Bacillus botulinus*, *J Bacteriol*, **4**(5), 555-570 551 (1919)
12. L.D. Smith, The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States, *Health Lab Sci* **15**(2), 74-80 (1978) (in eng)
13. K. Meyer, B. Dubovsky, The distribution of the spores of B. botulinus in the United States. IV., *J Infect Dis*, **31**, 559-594 (1922)
14. N. Dover, J.R. Barash, K.K. Hill, G. Xie, S.S. Arnon, Molecular characterization of a novel botulinum neurotoxin type H gene, *J Infect Dis*, **209**(2), 192-202 (2014)
15. J.R. Barash, S.S. Arnon, A novel strain of *Clostridium botulinum* that produces type B and type H botulinum toxins, *J Infect Dis*, **209**(2), 183-191 (2014)
16. S.E. Maslanka, C. Lúquez, J.K. Dykes, W.H. Tepp, C.L. Pier, S. Pellett, B.H. Raphael, S.R. Kalb, J.R. Barr, A. Rao, E.A. Johnson, A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin, *J Infect Dis*, (2015)
17. S. Pellett, W.H. Tepp, M. Bradshaw, S.R. Kalb, J.K. Dykes, G. Lin, E.M. Nawrocki, C.L. Pier, J.R. Barr, S.E. Maslanka, E.A. Johnson, Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified *Clostridium botulinum* Strain, *mSphere*, **1**(1), (2016)

18. Y. Fan, J.R. Barash, J. Lou, F. Conrad, J.D. Marks, S.S. Arnon, Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H, *J Infect Dis*, **213**(10), 1606-1614 (2016)
19. S.R. Kalb, J. Baudys, B.H. Raphael, J.K. Dykes, C. Lúquez, S.E. Maslanka, J.R. Barr, Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A), *Anal Chem*, **87**(7), 3911-3917 (2015)
20. G. Yao, S. Zhang, S. Mahrhold, K.H. Lam, D. Stern, K. Bagramyan, K. Perry, M. Kalkum, A. Rummel, M. Dong, R. Jin, N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A, *Nat Struct Mol Biol*, **23**(7), 656-662 (2016)
21. W. Pfenninger, Toxic immunologic and serologic relationship of *B. botulinus*, type C, and *B. parobotulinus*, *J Infect Dis*, **35**(4), 347-352 (1924)
22. K. Moriishi, M. Koura, N. Abe, N. Fujii, Y. Fujinaga, K. Inoue, K. Ogumad, Mosaic structures of neurotoxins produced from *Clostridium botulinum* types C and D organisms, *Biochim Biophys Acta*, **1307**(2), 123-126 (1996)
23. D.F. Giménez, A.S. Ciccarelli, Antigenic variations in type F botulinum toxins, *Medicina*, **32**(6), 596-606 (1972)
24. D.F. Giménez, Serological classification and typing of *Clostridium botulinum*, *Develop Biol Standards*, **32**, 175-183 (1976)
25. Y. Torii, M. Shinmura, T. Kohda, S. Kozaki, M. Takahashi, A. Ginnaga, Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin, *Toxicon*, **73**, 9-16 (2013)
26. W.H. Tepp, G. Lin, E.A. Johnson, Purification and characterization of a novel subtype a3 botulinum neurotoxin, *Appl Environ Microbiol*, **78**(9), 3108-3113 (2012)
27. BabyBIG package insert, <http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117160.pdf>
28. BAT, Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine), <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm345147.pdf>
29. D.F. Giménez, A.S. Ciccarelli, Studies on strain 84 of *Clostridium botulinum*, *Zentralbl Bakteriol Orig*, **215**, 212-220 (1970)
30. D.F. Giménez, J.A. Giménez, Serological subtypes of botulinal neurotoxins, Botulinum and Tetanus Neurotoxins. Neurotransmission and Biomedical Aspects.ed., B.R. DasGupta, Ed., Plenum Press, 1993, p 421-432
31. G. Franciosa, A. Maugliani, C. Scalfaro, P. Aureli, Evidence that plasmid-borne botulinum neurotoxin type B genes are widespread among *Clostridium botulinum* serotype B strains, *PLoS One*, **4**(3), e4829 (2009)
32. M.W. Peck, S.C. Stringer, A.T. Carter, *Clostridium botulinum* in the post-genomic era, *Food Microbiol*, **28**(2), 183-191 (2011)
33. S. Kozaki, Y. Kamata, T. Nishiki, H. Kakinuma, H. Maruyama, H. Takahashi, T. Karasawa, K. Yamakawa, S. Nakamura, Characterization of *Clostridium botulinum* type B neurotoxin associated with infant botulism in japan, *Infect Immun*, **66**(10), 4811-4816 (1998)
34. T.J. Smith, J. Lou, I.N. Geren, C.M. Forsyth, R. Tsai, S.L. Laporte, W.H. Tepp, M. Bradshaw, E.A. Johnson, L.A. Smith, J.D. Marks, Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization, *Infect Immun*, **73**(9), 5450-5457 (2005)

35. J.W. Arndt, M.J. Jacobson, E.E. Abola, C.M. Forsyth, W.H. Tepp, J.D. Marks, E.A. Johnson, R.C. Stevens, A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4, *J Mol Biol*, **362**(4), 733-742 (2006)
36. M. Sebaihia, M.W. Peck, N.P. Minton, N.R. Thomson, M.T. Holden, W.J. Mitchell, A.T. Carter, S.D. Bentley, D.R. Mason, L. Crossman, C.J. Paul, A. Ivens, M.H. Wells-Bennik, I.J. Davis, A.M. Cerdeno-Tarraga, C. Churcher, M.A. Quail, T. Chillingworth, T. Feltwell, A. Fraser, I. Goodhead, Z. Hance, K. Jagels, N. Larke, M. Maddison, S. Moule, K. Mungall, H. Norbertczak, E. Rabinowitsch, M. Sanders, M. Simmonds, B. White, S. Whithead, J. Parkhill, Genome sequence of a proteolytic (Group I) *Clostridium botulinum* strain Hall A and comparative analysis of the clostridial genomes, *Genome Res*, **17**(7), 1082-1092 (2007)
37. K.K. Hill, G. Xie, B.T. Foley, T.J. Smith, Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins, *Toxicon*, **107**(Pt A), 2-8 (2015)
38. C.H. Williamson, J.W. Sahl, T.J. Smith, G. Xie, B.T. Foley, L.A. Smith, R.A. Fernandez, M. Lindström, H. Korkeala, P. Keim, J. Foster, K. Hill, Comparative genomic analyses reveal broad diversity in botulinum-toxin-producing Clostridia, *BMC Genomics*, **17**(1), 180 (2016) (in eng)
39. T. Binz, H. Kurazono, M. Wille, J. Frevert, K. Wernars, H. Niemann, The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins, *J Biol Chem*, **265**(16), 9153-9158 (1990)
40. D.E. Thompson, J.K. Brehm, J.D. Oultram, T.J. Swinfield, C.C. Shone, T. Atkinson, J. Melling, N.P. Minton, The complete amino acid sequence of the *Clostridium botulinum* type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene, *Eur J Biochem*, **189**(1), 73-81 (1990)
41. S.M. Whelan, M.J. Elmore, N.J. Bodsworth, J.K. Brehm, T. Atkinson, N.P. Minton, Molecular cloning of the *Clostridium botulinum* structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence, *Appl Environ Microbiol*, **58**(8), 2345-2354 (1992)
42. D. Hauser, M.W. Eklund, H. Kurazono, T. Binz, H. Niemann, D.M. Gill, P. Boquet, M.R. Popoff, Nucleotide sequence of *Clostridium botulinum* C1 neurotoxin, *Nucleic Acids Res*, **18**(16), 4924 (1990)
43. T. Binz, H. Kurazono, M.R. Popoff, M.W. Eklund, G. Sakaguchi, S. Kozaki, K. Krieglstein, A. Henschen, D.M. Gill, H. Niemann, Nucleotide sequence of the gene encoding *Clostridium botulinum* neurotoxin type D, *Nucleic Acids Res*, **18**(18), 5556 (1990)
44. S.M. Whelan, M.J. Elmore, N.J. Bodsworth, T. Atkinson, N.P. Minton, The complete amino acid sequence of the *Clostridium botulinum* type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene, *Eur J Biochem*, **204**(2), 657-667 (1992)
45. A.K. East, P.T. Richardson, D. Allaway, M.D. Collins, T.A. Roberts, D.E. Thompson, Sequence of the gene encoding type F neurotoxin of *Clostridium botulinum*, *FEMS Microbiol Lett*, **75**(2-3), 225-230 (1992)
46. K. Campbell, M.D. Collins, A.K. East, Nucleotide sequence of the gene coding for *Clostridium botulinum* (*Clostridium argentinense*) type G neurotoxin: genealogical comparison with other clostridial neurotoxins, *Biochim Biophys Acta*, **1216**(3), 487-491 (1993)
47. S. Poulet, D. Hauser, M. Quanz, H. Niemann, M.R. Popoff, Sequences of the botulinal neurotoxin E derived from *Clostridium botulinum* type E (strain Beluga) and *Clostridium*

- butyricum* (strains ATCC 43181 and ATCC 43755), *Biochem Biophys Res Commun*, **183**(1), 107-113 (1992)
48. A. Willems, A.K. East, P.A. Lawson, M.D. Collins, Sequence of the gene coding for the neurotoxin of *Clostridium botulinum* type A associated with infant botulism: comparison with other clostridial neurotoxins, *Res Microbiol*, **144**(7), 547-556 (1993)
49. R.A. Hutson, Y. Zhou, M.D. Collins, E.A. Johnson, C.L. Hatheway, H. Sugiyama, Genetic characterization of *Clostridium botulinum* type A containing silent type B neurotoxin gene sequences, *J Biol Chem*, **271**(18), 10786-10792 (1996)
50. R.A. Hutson, M.D. Collins, A.K. East, D.E. Thompson, Nucleotide sequence of the gene coding for non-proteolytic *Clostridium botulinum* type B neurotoxin: comparison with other clostridial neurotoxins, *Curr Microbiol*, **28**(2), 101-110 (1994)
51. J.A. Santos-Buelga, M.D. Collins, A.K. East, Characterization of the genes encoding the botulinum neurotoxin complex in a strain of *Clostridium botulinum* producing type B and F neurotoxins, *Curr Microbiol*, **37**(5), 312-318 (1998)
52. A.K. East, M. Bhandari, S. Hielm, M.D. Collins, Analysis of the botulinum neurotoxin type F gene clusters in proteolytic and nonproteolytic *Clostridium botulinum* and *Clostridium baratii*, *Curr Microbiol*, **37**(4), 262-268 (1998) (in eng)
53. G. Franciosa, J.L. Ferreira, C.L. Hatheway, Detection of type A, B, and E botulism neurotoxin genes in *Clostridium botulinum* and other *Clostridium* species by PCR: evidence of unexpressed type B toxin genes in type A toxigenic organisms, *J Clin Microbiol*, **32**(8), 1911-1917 (1994)
54. K.K. Hill, T.J. Smith, Genetic diversity within *Clostridium botulinum* serotypes, botulinum neurotoxin gene clusters and toxin subtypes, *Curr Top Microbiol Immunol*, **364**, 1-20 (2013)
55. S.R. Kalb, J. Baudys, R.P. Webb, P. Wright, T.J. Smith, L.A. Smith, R. Fernandez, B.H. Raphael, S.E. Maslanka, J.L. Pirkle, J.R. Barr, Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5, *FEBS Lett*, **586**(2), 109-115 (2012)
56. C. Shone, P. Wilton-Smith, N. Appleton, P. Hambleton, N. Modi, S. Gatley, J. Melling, Monoclonal antibody-based immunoassay for type A *Clostridium botulinum* toxin is comparable to the mouse bioassay, *Appl Environ Microbiol*, **50**(1), 63-67 (1985)
57. S. Notermans, S. Kozaki, Y. Kamata, G. Sakaguchi, Use of monoclonal antibodies in enzyme linked immunosorbent assay (ELISA) for detection of botulinum type B toxins, *Jpn J Med Sci Biol*, **37**(3), 137-140 (1984)
58. K. Oguma, T. Agui, B. Syuto, K. Kimura, H. Iida, S. Kubo, Four different monoclonal antibodies against type C1 toxin of *Clostridium botulinum*, *Infect Immun*, **38**(1), 14-20 (1982)
59. S. Kozaki, Y. Kamata, T. Nagai, J. Ogasawara, G. Sakaguchi, The use of monoclonal antibodies to analyze the structure of *Clostridium botulinum* type E derivative toxin, *Infect Immun*, **52**(3), 786-791 (1986)
60. A.M. Gibson, N.K. Modi, T.A. Roberts, P. Hambleton, J. Melling, Evaluation of a monoclonal antibody-based immunoassay for detecting type B *Clostridium botulinum* toxin produced in pure culture and an inoculated model cured meat system, *J Appl Bacteriol*, **64**(4), 285-291 (1988)
61. S. Kozaki, S. Nakaue, Y. Kamata, Immunological characterization of the neurotoxin produced by *Clostridium botulinum* type A associated with infant botulism in Japan, *Microbiol Immunol*, **39**(10), 767-774 (1995)

62. K.K. Hill, T.J. Smith, C.H. Helma, L.O. Ticknor, B.T. Foley, R.T. Svensson, J.L. Brown, E.A. Johnson, L.A. Smith, R.T. Okinaka, P.J. Jackson, J.D. Marks, Genetic diversity among Botulinum Neurotoxin-producing clostridial strains, *J Bacteriol*, **189**(3), 818-832 (2007)
63. K. Umeda, Y. Seto, T. Kohda, M. Mukamoto, S. Kozaki, Genetic characterization of *Clostridium botulinum* associated with type B infant botulism in Japan, *J Clin Microbiol*, **47**(9), 2720-2728 (2009)
64. A.T. Carter, C.J. Paul, D.R. Mason, S.M. Twine, M.J. Alston, S.M. Logan, J.W. Austin, M.W. Peck, Independent evolution of neurotoxin and flagellar genetic loci in proteolytic *Clostridium botulinum*, *BMC Genomics*, **10**, 115 (2009)
65. M.W. Peck, Biology and genomic analysis of *Clostridium botulinum*, *Adv Microb Physiol*, **55**, 183-265, 320 (2009)
66. B.H. Raphael, M.J. Choudoir, C. Lúquez, R. Fernandez, S.E. Maslanka, Sequence diversity of genes encoding botulinum neurotoxin type F, *Appl Environ Microbiol*, **76**(14), 4805-4812 (2010)
67. M.J. Jacobson, G. Lin, W. Tepp, J. Dupuy, P. Stenmark, R.C. Stevens, E.A. Johnson, Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from *Clostridium botulinum* strain A661222, *Appl Environ Microbiol*, **77**(12), 4217-4222 (2011)
68. B.H. Raphael, M. Lautenschlager, S.R. Kalb, L.I. de Jong, M. Frace, C. Lúquez, J.R. Barr, R.A. Fernandez, S.E. Maslanka, Analysis of a unique *Clostridium botulinum* strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype, *BMC Microbiol*, **12**, 245 (2012)
69. P. Wangroongsarb, T. Kohda, C. Jittaprasartsin, K. Suthivarakom, T. Kamthlang, K. Umeda, P. Sawanpanyalert, S. Kozaki, K. Ikuta, Molecular characterization of *Clostridium botulinum* isolates from foodborne outbreaks in Thailand, 2010, *PLoS One*, **9**(1), e77792 (2014)
70. K.A. Weedmark, D.L. Lambert, P. Mabon, K.L. Hayden, C.J. Urfano, D. Leclair, G. Van Domselaar, J.W. Austin, C.R. Corbett, Two novel toxin variants revealed by whole-genome sequencing of 175 *Clostridium botulinum* type E strains, *Appl Environ Microbiol*, **80**(20), 6334-6345 (2014)
71. S. Kull, K.M. Schulz, J. Weisemann, S. Kirchner, T. Schreiber, A. Bollenbach, P.W. Dabrowski, A. Nitsche, S.R. Kalb, M.B. Dorner, J.R. Barr, A. Rummel, B.G. Dorner, Isolation and functional characterization of the novel *Clostridium botulinum* neurotoxin A8 subtype, *PLoS One*, **10**(2), e0116381 (2015)
72. C. Mazuet, J. Sautereau, C. Legeay, C. Bouchier, P. Bouvet, M.R. Popoff, An atypical outbreak of food-borne botulism due to *Clostridium botulinum* types B and E from ham, *J Clin Microbiol*, **53**(2), 722-726 (2015)
73. J. Strotmeier, S. Gu, S. Jutzi, S. Mahrhold, J. Zhou, A. Pich, T. Eichner, H. Bigalke, A. Rummel, R. Jin, T. Binz, The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites, *Mol Microbiol*, **81**(1), 143-156 (2011)
74. L. Peng, W.H. Tepp, E.A. Johnson, M. Dong, Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors, *PLoS Pathog*, **7**(3), e1002008 (2011)
75. L. Peng, R.P. Berntsson, W.H. Tepp, R.M. Pitkin, E.A. Johnson, P. Stenmark, M. Dong, Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins, *J Cell Sci*, **125**(Pt 13), 3233-3242 (2012)

76. C.L. Pier, C. Chen, W.H. Tepp, G. Lin, K.D. Janda, J.T. Barbieri, S. Pellett, E.A. Johnson, Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1, *FEBS Lett*, **585**(1), 199-206 (2011)
77. R.C. Whitmarsh, W.H. Tepp, M. Bradshaw, G. Lin, C.L. Pier, J.M. Scherf, E.A. Johnson, S. Pellett, Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro, *Infect Immun*, **81**(10), 3894-3902 (2013)
78. M. Bradshaw, W.H. Tepp, R.C. Whitmarsh, S. Pellett, E.A. Johnson, Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic *Clostridium botulinum* Expression System, *Appl Environ Microbiol*, **80**(23), 7415-7422 (2014)
79. R.C. Whitmarsh, W.H. Tepp, E.A. Johnson, S. Pellett, Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells, *PLoS One*, **9**(2), e90252 (2014)
80. S. Pellett, W.H. Tepp, R.C. Whitmarsh, M. Bradshaw, E.A. Johnson, In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5, *Toxicon*, **107**(Pt A), 37-42 (2015)
81. T.E. Macdonald, C.H. Helma, Y. Shou, Y.E. Valdez, L.O. Ticknor, B.T. Foley, S.W. Davis, G.E. Hannett, C.D. Kelly-Cirino, J.R. Barash, S.S. Arnon, M. Lindström, H. Korkeala, L.A. Smith, T.J. Smith, K.K. Hill, Analysis of *Clostridium botulinum* serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing, *Appl Environ Microbiol*, **77**(24), 8625-8634 (2011)
82. Y. Chen, H. Korkeala, J. Aarnikunnas, M. Lindström, Sequencing the botulinum neurotoxin gene and related genes in *Clostridium botulinum* type E strains reveals orfx3 and a novel type E neurotoxin subtype, *J Bacteriol*, **189**(23), 8643-8650 (2007)
83. C.L. Hatheway, Bacteriology and pathology of neurotoxic clostridia., Botulinum and Tetanus Neurotoxins. Neurotransmission and Biomedical Aspects.ed., B.R. DasGupta, Ed., Plenum Press, 1993, p 491-503
84. A.T. Carter, M.W. Peck, Genomes, neurotoxins and biology of *Clostridium botulinum* Group I and Group II, *Res Microbiol*, **166**(4), 303-317 (2015)
85. T.J. Smith, K.K. Hill, G. Xie, B.T. Foley, C.H. Williamson, J.T. Foster, S.L. Johnson, O. Chertkov, H. Teshima, H.S. Gibbons, L.A. Johnsky, M.A. Karavis, L.A. Smith, Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes, *Infect Genet Evol*, **30**, 102-113 (2015)
86. H. Skarin, T. Håfström, J. Westerberg, B. Segerman, *Clostridium botulinum* group III: a group with dual identity shaped by plasmids, phages and mobile elements, *BMC Genomics*, **12**, 185 (2011)
87. R. Keto-Timonen, A. Heikinheimo, E. Eerola, H. Korkeala, Identification of *Clostridium* species and DNA fingerprinting of *Clostridium perfringens* by amplified fragment length polymorphism analysis, *J Clin Microbiol*, **44**(11), 4057-4065 (2006)
88. J.C. Suen, C.L. Hatheway, A.G. Steigerwalt, D.J. Brenner, Genetic confirmation of identities of neurotoxicogenic *Clostridium baratii* and *Clostridium butyricum* implicated as agents of infant botulism, *J Clin Microbiol*, **26**(10), 2191-2192 (1988)
89. M.R. Weigand, A. Pena-Gonzalez, T.B. Shirey, R.G. Broeker, M.K. Ishaq, K.T. Konstantinidis, B.H. Raphael, Implications of Genome-Based Discrimination between

- Clostridium botulinum* Group I and *Clostridium sporogenes* Strains for Bacterial Taxonomy, *Appl Environ Microbiol*, **81**(16), 5420-5429 (2015)
90. S. Fillo, F. Giordani, A. Anselmo, A. Fortunato, A.M. Palozzi, R. De Santis, A. Ciammaruconi, F. Spagnolo, F. Anniballi, A. Fiore, B. Auricchio, D. De Medici, F. Lista, Draft Genome Sequence of *Clostridium botulinum* B2 450 Strain from Wound Botulism in a Drug User in Italy, *Genome Announc*, **3**(2), (2015)
 91. A.T. Carter, S.C. Stringer, M.D. Webb, M.W. Peck, The type F6 neurotoxin gene cluster locus of group II *Clostridium botulinum* has evolved by successive disruption of two different ancestral precursors, *Genome Biol Evol*, **5**(5), 1032-1037 (2013)
 92. M.K. Lindström, H.M. Jankola, S. Hielm, E.K. Hyytia, H.J. Korkeala, Identification of *Clostridium botulinum* with API 20 A, Rapid ID 32 A and RapID ANA II, *FEMS Immunol Med Microbiol*, **24**(3), 267-274 (1999)
 93. K.M. Marshall, M. Bradshaw, S. Pellett, E.A. Johnson, Plasmid encoded neurotoxin genes in *Clostridium botulinum* serotype A subtypes, *Biochem Biophys Res Commun*, **361**(1), 49-54 (2007)
 94. T.J. Smith, K.K. Hill, B.T. Foley, J.C. Detter, A.C. Munk, D.C. Bruce, N.A. Doggett, L.A. Smith, J.D. Marks, G. Xie, T.S. Brettin, Analysis of the neurotoxin complex genes in *Clostridium botulinum* A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids, *PLoS One*, **2**(12), e1271 (2007)
 95. S.C. Stringer, A.T. Carter, M.D. Webb, E. Wachnicka, L.C. Crossman, M. Sebahia, M.W. Peck, Genomic and physiological variability within Group II (non-proteolytic) *Clostridium botulinum*, *BMC Genomics*, **14**, 333 (2013)
 96. A.T. Carter, J.W. Austin, K.A. Weedmark, M.W. Peck, Evolution of Chromosomal *Clostridium botulinum* Type E Neurotoxin Gene Clusters: Evidence Provided by Their Rare Plasmid-Borne Counterparts, *Genome Biol Evol*, **8**(3), 540-555 (2016)
 97. M. Takeda, K. Tsukamoto, T. Kohda, M. M. M. Mukamoto, S. Kozaki, Characterization of the neurotoxin produced by isolates associated with avian botulism, *Avian diseases*, **49**, 376-381 (2005)
 98. O. Sonnabend, W. Sonnabend, R. Heinzle, T. Sigrist, R. Dirnhofer, U. Krech, Isolation of *Clostridium botulinum* type G and identification of type G botulin toxin in humans: report of five sudden unexpected deaths, *J Infect Dis*, **143**(1), 22-27 (1981)
 99. E. van Ermengem, A new anaerobic bacillus and its relation to botulism (originally published as "Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten 26:1-56, 1897), *Rev Infect Dis*, **1**(4), 701-719 (1897)
 100. G. Landmann, Ueber die ursache der Darmstadter bohnenvergiftung, *Hyg Rundschau*, **XIV**, 449 (1904)
 101. B.R. Das Gupta, H. Sugiyama, Role of a protease in natural activation of *Clostridium botulinum* neurotoxin, *Infect Immun*, **6**(4), 587-590 (1972)
 102. B.R. Das Gupta, H. Sugiyama, A common subunit structure in *Clostridium botulinum* type A, B and E toxins, *Biochem Biophys Res Commun*, **48**(1), 108-112 (1972)
 103. T.J. Smith, *Clostridium botulinum* genomes and genetic diversity, Molecular Aspects of Botulinum Neurotoxins, K.A. Foster, Ed., Springer, 2014, p 207-228
 104. T.J. Smith, K.K. Hill, B.H. Raphael, Historical and current perspectives on *Clostridium botulinum* diversity, *Res Microbiol*, (2014)

105. S. Mahrhold, A. Rummel, H. Bigalke, B. Davletov, T. Binz, The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves, *FEBS Lett*, **580**(8), 2011-2014 (2006)
106. M. Dong, F. Yeh, W.H. Tepp, C. Dean, E.A. Johnson, R. Janz, E.R. Chapman, SV2 is the protein receptor for botulinum neurotoxin A, *Science*, **312**(5773), 592-596 (2006)
107. M. Dong, D.A. Richards, M.C. Goodnough, W.H. Tepp, E.A. Johnson, E.R. Chapman, Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells, *J Cell Biol*, **162**(7), 1293-1303 (2003)
108. M. Dong, W.H. Tepp, H. Liu, E.A. Johnson, E.R. Chapman, Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons, *J Cell Biol*, **179**(7), 1511-1522 (2007)
109. M. Dong, H. Liu, W.H. Tepp, E.A. Johnson, R. Janz, E.R. Chapman, Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons, *Mol Biol Cell*, **19**(12), 5226-5237 (2008)
110. S. Mahrhold, J. Strotmeier, C. Garcia-Rodriguez, J. Lou, J.D. Marks, A. Rummel, T. Binz, Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E, *Biochem J*, **453**(1), 37-47 (2013)
111. Z. Fu, C. Chen, J.T. Barbieri, J.J. Kim, M.R. Baldwin, Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F, *Biochemistry*, **48**(24), 5631-5641 (2009)
112. A. Rummel, K. Hafner, S. Mahrhold, N. Darashchonak, M. Holt, R. Jahn, S. Beermann, T. Karnath, H. Bigalke, T. Binz, Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor, *J Neurochem*, **110**(6), 1942-1954 (2009)
113. A. Rummel, T. Karnath, T. Henke, H. Bigalke, T. Binz, Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G, *J Biol Chem*, **279**(29), 30865-30870 (2004)

Table 1. Synaptic vesicle proteins that act as receptors for botulinum neurotoxins.

Serotype	Protein receptor	Binding site	References
BoNT/A	N-glycosylated SV2A, B, C	H _{CN} -H _{CC}	[20,105,106]
BoNT/B	Synaptotagmin I & II	H _{CC}	[33,107,108]
BoNT/C	-----*		[73]
BoNT/D	N-glycosylated SV2A, B, C		[74]
BoNT/DC	Synaptotagmin I & II	H _{CC}	[75]
BoNT/E	N-glycosylated SV2A, B	H _{CN} -H _{CC}	[109,110]
BoNT/F	N-glycosylated SV2A, B, C		[111,112]
BoNT/G	Synaptotagmin I & II	H _{CC}	[108,113]

*BoNT/C interacts with ganglioside only; there is no protein receptor identified so far.

Table 2. The enzymatic targets and cleavage sites of various botulinum neurotoxins. The table is a modification of [7] with additional data from [55].

SNARE isoform	BoNT cleavage sites				
	BoNT/E		BoNT/A	BoNT/C	
	↓		↓	↓	
SNAP-25a, b	--QNRQID R IMEKADSNKTRIDEAN Q R ATKMLGSG				
	BoNT/F5	BoNT/F	BoNT/D	BoNT/B	BoNT/G
	↓	↓	↙	↓	↓
VAMP-1	- DKVL ERD Q K LSELDDRADALQAGAS Q FESS A AKLKRKYWW				
VAMP-2	- DKVL ERD Q K LSELDDRADALQAGAS Q FETS A AKLKRKYWW--				
	BoNT/C				
	↓				
Syntaxin 1A/C; 1B, 2 & 3	--EHAVDYVERAVSDTK K AVKYQSKARR K KIM				

Table 3. Representative strains of BoNT subtypes. Note that these prototype strains were used to produce the comparisons in Tables 5-9.

serotype	subtype	representative strain	source/date	sequence accession #
BoNT/A	A1	ATCC 3502	peas/California, 1922	CAL82360
	A2	Kyoto-F	infant botulism/Japan, 1978	CAA51824
	A3	Loch Maree	duck paste/Scotland, 1922	ACA57525
	A4	strain 657	infant botulism/Texas, 1976	ACQ51417
	A5	H04402 065	wound botulism (heroin), 2004	ACG50065
	A6	CDC 41370	food/Mexico	ACW83608
	A7	2008-148	enchiladas/France, 2008	AFV13854
	A8	Chemnitz	green bean salad/Germany, 2007	AJA05787
BoNT/B	B1	okra	Okra, Tennessee, 1939	ACA46990
	B2	strain 111	infant botulism/Japan,	BAC22064
	B3	CDC 795	Unknown	ABM73977
	B4	Eklund 17B	marine sediments/Pacific coast, 1965	ABM73987
	B5	strain 657	infant botulism/Texas, 1976	ACQ51206
	B6	Osaka05	infant botulism/Japan, 2005	BAF91946
	B7	Bac-04-07755	infant botulism/New York, 2004	AFD33678
	B8	Maehongson	foodborne botulism/Thailand, 2010	AFN61309
BoNT/C	C1	Stockholm	mink/Sweden	BAA14235
	CD	6813	soil/Maryland	BAA08418
BoNT/D	D	1873	ham/Chad, 1958	EES90380
	DC	VPI 5995	South Africa	ABP48747
BoNT/E	E1	Beluga	whale/Alaska, 1952	CAA43999
	E2	CDC 5247	Unknown	EF028404
	E3	Alaska E43	Alaska	ABM73980
	E4	BL5262	infant botulism/Italy, 1984	BAC05434
	E5	LCL155	soybean-wax gourd paste/China	AAQ16542
	E6	K35	fish/Finland, Baltic Sea	CAM91125
	E7	IBCA97-0192	whitefish/California, 1997	AER11391
	E8	Bac-02-06430	round goby/Lake Erie, 2002	AER11392
	E9	CDC 66177	environmental/Argentina	AFV91339
	E10	FWKR11E1	freshwater/Canada	KF861920
	E11	SW280E	seawater/Canada	KF861879
	E12	84-10	ham/France, 2009	KF929215
BoNT/F	F1	Langeland	duck paste/Denmark, 1958	ABS41202
	F2	CDC 3281	infant botulism/Texas, 1982	CAA73972
	F3	VPI4257 (F160)	soil/Argentina, ~1968	ADA79575
	F4	CDC54089	anchovies/Argentina, 1984	GU213221
	F5	CDC54075	soil/Argentina, 1978	GU213212
	F6	Eklund 202F	marine sediments/Pacific coast, 1965	AAA23263
	F7	Sullivan	adult botulism/New York, 2007	ADK48765
	F8	I357	asparagus/Italy, 2005	AUCZ00000000
BoNT/G		CDC 2741	autopsy specimen/Switzerland, 1978	KIE44899
BoNT/FA (H)*		CFSAN024410 (IBCA 10-7060)	infant botulism, non-USA, 2010	KGO15617

*This strain is known as FA, H and HA.

Table 4. Amino Acid Differences Among BoNT Serotypes*

	A1	B1	C1	D	E3	F1	G
A1	-----	62.5%	69.6%	68.8%	62.3%	61.3%	62.0%
B1		-----	69.2%	67.4%	64.1%	62.6%	42.9%
C1			-----	48.6%	69.1%	69.1%	67.5%
D				-----	68.4%	67.3%	66.0%
E3					-----	37.2%	63.6%
F1						-----	63.2%
G							-----

*Differences of <50% are in bold font.

Table 5. Amino Acid Differences Among BoNT/A Subtypes

subtype		Maximum between-subtype differences (%)								Maximum within-subtype difference (%)
		A1	A2	A3	A4	A5	A6	A7	A8	
A1	n = 80	-----	10.1	15.4	10.6	2.9	4.3	6.2	6.7	0.5
A2	n = 34		-----	7.0	11.7	9.7	8.3	10.3	6.6	2.5*
A3	n = 4			-----	15.6	15.0	13.8	15.2	12.3	0.2
A4	n = 1				-----	12.6	12.2	13.3	10.9	-----
A5	n = 3					-----	4.2	5.6	6.6	0.2
A6	n = 2						-----	7.0	7.0	0.1
A7	n = 1							-----	8.7	-----
A8	n = 2								-----	0.1

*Within-subtype differences decrease to 0.8% after removal of CDC 2171.

Table 6. Amino Acid Differences Among BoNT/B Subtypes

subtype		Maximum between-subtype differences (%)								Maximum within-subtype difference (%)
		B1	B2	B3	B4	B5	B6	B7	B8	
B1	n = 18	-----	4.4	4.0	6.8	3.9	3.9	5.3	4.6	1.1
B2	n = 38		-----	1.6	6.1	4.7	1.6	4.2	4.2	2.9*
B3	n = 1			-----	6.3	4.3	1.9	4.3	2.5	-----
B4	n = 16				-----	7.1	6.9	6.4	7.1	1.9
B5	n = 9					-----	4.6	5.7	5.4	0.8
B6	n = 6						-----	4.9	4.4	0.2
B7	n = 2							-----	5.6	0.1
B8	n = 1								-----	-----

*When 5 outliers are removed, the within-subtype difference decreases to 0.9%. Where differences are <2.6%, the percentage difference is shown in red.

Table 7. Amino Acid Differences Among BoNT/C and BoNT/D Subtypes

subtype		Maximum between-subtype differences (%)				Maximum within-subtype difference (%)
		C1	C/D	D	D/C	
C1	n = 11	-----	24.2	48.8	35.3	0.1
C/D	n = 8		-----	30.7	48.2	2.0*
D	n = 2			-----	23.5	1.8
D/C	n = 2				-----	0.1

*When 2 outliers are removed, the within-subtype difference decreases to 0.3%.

Table 8. Amino Acid Differences Among BoNT/E Subtypes

subtype		Maximum between-subtype differences (%)												Maximum within-subtype difference (%)
		E1	E2	E3	E4	E5	E6	E7	E8	E9	E10	E11	E12	
E1	n = 23	-----	0.9	1.8	2.7	3.1	3.0	2.1	3.8	10.9	4.6	6.6	7.1	0.2
E2	n = 2		-----	2.6	3.0	3.7	3.6	2.9	3.0	10.7	4.2	6.2	6.9	0.0
E3	n = 143			-----	4.4	4.9	4.1	2.6	4.3	11.3	5.3	7.4	7.5	0.6
E4	n = 3				-----	5.1	3.1	3.8	3.9	10.1	5.2	7.3	7.5	0.0
E5	n = 11					-----	5.2	5.2	5.9	10.6	6.6	8.1	6.5	0.0
E6	n = 3						-----	3.6	3.2	11.8	4.4	6.9	9.0	0.1
E7	n = 2							-----	1.7	10.9	3.2	6.5	7.6	0.0
E8	n = 1								-----	10.6	2.1	5.6	8.1	-----
E9	n = 1									-----	10.6	11.0	8.6	-----
E10	n = 36										-----	4.3	8.1	0.8
E11	n = 9											-----	9.0	0.0
E12	n=1												-----	-----

Where differences are <2.6%, the percentage difference is shown in red.

Table 9. Amino Acid Differences Among BoNT/F Subtypes

subtype		Maximum between-subtype differences (%)								Maximum within-subtype difference (%)
		F1	F2	F3	F4	F5	F6	F7	F8	
F1	n = 10	-----	16.6	16.1	7.8	30.2	12.6	26.3	3.7	0.1
F2	n = 4		-----	3.0	16.5	26.0	10.2	31.4	16.9	0.3
F3	n = 2			-----	16.2	26.0	10.2	31.1	16.5	0.1
F4	n = 11				-----	30.6	13.1	28.1	7.4	0.6
F5	n = 7					-----	26.4	36.2	30.9	0.1
F6	n = 7						-----	30.2	13.1	0.2
F7	n = 9							-----	28.0	1.7*
F8	n = 1								-----	

*Within-subtype differences decrease to 0.8% after removal of ATCC43756.




Figure 1. Dendrogram showing the relationship of all published/publicly posted BoNT subtypes. The dendrograms were generated using ClustalW using representatives listed in Table 3. BoNT/FA (H) is also known as BoNT/HA.




Figure 2. Dendrogram showing the relationships of BoNT/A subtypes. A total of 127 amino acid sequences were analyzed. The dendrogram scale is similar in Figures 2-5 to allow for visual comparison of subtype differences among BoNT/A, /B, /C, /D, and /E serotypes.




Figure 3. Dendrogram showing the relationships of BoNT/B subtypes. A total of 91 amino acid sequences were analyzed. The BoNT/B subtypes show the closest relationships, with amino acid differences ranging from 1.6-7.1%.




Figure 4. Dendrogram showing the relationships of BoNT/C and /D subtypes. A total of 23 amino acid sequences were analyzed. The mosaic nature of the BoNT/C and /D subtypes results in large differences in amino acid sequence (23.5-48.8%).




Figure 5. Dendrogram showing the relationships of BoNT/E subtypes. A total of 235 amino acid sequences were analyzed.




Figure 6. Dendrogram showing the relationships of BoNT/F subtypes. A total of 52 amino acid sequences were analyzed. The scale for this dendrogram is significantly smaller than with the others due to the wider range of identity differences (7.8-36.2%) within this serotype.